Albert Labs International（ABRT）株式概要アルバート・ラボ・インターナショナル社は、バイオ医薬品の創薬企業で、カナダと英国において、緊急かつアンメットニーズのある患者のためのサイケデリック補助療法のための薬剤を研究開発している。 詳細ABRT ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析マイナスの株主資本 収益が 100 万ドル未満 ( CA$0 )意味のある時価総額がありません ( CA$372K )株式の流動性は非常に低い +1 さらなるリスクすべてのリスクチェックを見るABRT Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCA$Current PriceCA$0.005該当なし内在価値ディスカウントEst. Revenue$PastFuture-7m12016201920222025202620282031Revenue CA$1.0Earnings CA$0.2AdvancedSet Fair ValueView all narrativesAlbert Labs International Corp. 競合他社Cytophage TechnologiesSymbol: TSXV:CYTO.HMarket cap: CA$338.4kVaxil BioSymbol: TSXV:VXLMarket cap: CA$717.1kEntheon BiomedicalSymbol: CNSX:ENBI.XMarket cap: CA$762.2kPsyence GroupSymbol: CNSX:PSYGMarket cap: CA$1.9m価格と性能株価の高値、安値、推移の概要Albert Labs International過去の株価現在の株価CA$0.00552週高値CA$0.03552週安値CA$0.005ベータ3.131ヶ月の変化0%3ヶ月変化0%1年変化-50.00%3年間の変化n/a5年間の変化n/aIPOからの変化-98.00%最新ニュースNew Risk • Jun 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$492k free cash flow). Shares are highly illiquid. Negative equity (-CA$443k). Revenue is less than US$1m. Market cap is less than US$10m (CA$744.1k market cap, or US$541.9k). Minor Risk Latest financial reports are more than 6 months old (reported September 2023 fiscal period end).Board Change • Mar 13No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jan 11No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Dec 08No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 19Albert Labs International Corp. Appoints Shabir Hasham to Its Board of DirectorsAlbert Labs International Corp. announced the appointment of Dr. Shabir Hasham to its Board of Directors. With an impressive 20 years of distinguished industry experience, Dr. Hasham brings a wealth of expertise to guide Albert Labs in its mission to revolutionize mental health solutions. Dr. Hasham's exceptional career is marked by his proficiency in navigating regulatory bodies, including the FDA and MHRA, ensuring successful product launches and compliance. His regulatory acumen aligns seamlessly with Albert Labs' commitment to delivering innovative mental health solutions. As the former EU Medical Director for the Neuroscience Franchise at Novartis, Dr. Hasham played a pivotal role in advancing pharmaceutical solutions. His leadership is a testament to his deep understanding of the complexities involved in bringing transformative medicines to market. Dr. Shabir Hasham's arrival marks a reunion with former team members, including Chief Medical Officer Dr. Malcolm Barrett Johnson and Chief Operations Officer Santoke Naal. His past collaborations with these key individuals, particularly during their tenure at Novartis, underscore Dr. Hasham's exceptional ability to drive successful outcomes in a collaborative environment. In addition to his 20 years of experience, Dr. Shabir Hasham will be progressively taking on an increased leadership role within Albert Labs. His informal leadership style, combined with strategic planning and operational excellence, aligns seamlessly with the company's vision for transformative solutions in mental health pharmaceuticals. Dr. Hasham possesses a unique proficiency in dealing with biotechnology and healthcare investment funds. His strategic insights have effectively guided investments, contributing to the success of various projects. Dr. Hasham's ability to communicate complex ideas in the right manner has been instrumental in securing support from investment entities, and ensuring alignment with organizational goals. Albert Labs looks forward to leveraging Dr. Shabir Hasham's multifaceted expertise as the company continues its pursuit of excellence in mental health pharmaceuticals.お知らせ • Sep 07Albert Labs International Corp. Announces CEO ChangesAlbert Labs Management and Board of Director Announcement Effective immediately, Michael Raymont has resigned from his position of chief executive officer and director of Albert Labs International Corp., and Mike Thompson has resigned from the board of directors. The board of directors extends its sincerest gratitude to Mr. Raymont and Mr. Thompson for their contributions to the company. Chand Jagpal will be acting as the interim chief executive officer until a suitable candidate is found.最新情報をもっと見るRecent updatesNew Risk • Jun 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$492k free cash flow). Shares are highly illiquid. Negative equity (-CA$443k). Revenue is less than US$1m. Market cap is less than US$10m (CA$744.1k market cap, or US$541.9k). Minor Risk Latest financial reports are more than 6 months old (reported September 2023 fiscal period end).Board Change • Mar 13No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jan 11No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Dec 08No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 19Albert Labs International Corp. Appoints Shabir Hasham to Its Board of DirectorsAlbert Labs International Corp. announced the appointment of Dr. Shabir Hasham to its Board of Directors. With an impressive 20 years of distinguished industry experience, Dr. Hasham brings a wealth of expertise to guide Albert Labs in its mission to revolutionize mental health solutions. Dr. Hasham's exceptional career is marked by his proficiency in navigating regulatory bodies, including the FDA and MHRA, ensuring successful product launches and compliance. His regulatory acumen aligns seamlessly with Albert Labs' commitment to delivering innovative mental health solutions. As the former EU Medical Director for the Neuroscience Franchise at Novartis, Dr. Hasham played a pivotal role in advancing pharmaceutical solutions. His leadership is a testament to his deep understanding of the complexities involved in bringing transformative medicines to market. Dr. Shabir Hasham's arrival marks a reunion with former team members, including Chief Medical Officer Dr. Malcolm Barrett Johnson and Chief Operations Officer Santoke Naal. His past collaborations with these key individuals, particularly during their tenure at Novartis, underscore Dr. Hasham's exceptional ability to drive successful outcomes in a collaborative environment. In addition to his 20 years of experience, Dr. Shabir Hasham will be progressively taking on an increased leadership role within Albert Labs. His informal leadership style, combined with strategic planning and operational excellence, aligns seamlessly with the company's vision for transformative solutions in mental health pharmaceuticals. Dr. Hasham possesses a unique proficiency in dealing with biotechnology and healthcare investment funds. His strategic insights have effectively guided investments, contributing to the success of various projects. Dr. Hasham's ability to communicate complex ideas in the right manner has been instrumental in securing support from investment entities, and ensuring alignment with organizational goals. Albert Labs looks forward to leveraging Dr. Shabir Hasham's multifaceted expertise as the company continues its pursuit of excellence in mental health pharmaceuticals.お知らせ • Sep 07Albert Labs International Corp. Announces CEO ChangesAlbert Labs Management and Board of Director Announcement Effective immediately, Michael Raymont has resigned from his position of chief executive officer and director of Albert Labs International Corp., and Mike Thompson has resigned from the board of directors. The board of directors extends its sincerest gratitude to Mr. Raymont and Mr. Thompson for their contributions to the company. Chand Jagpal will be acting as the interim chief executive officer until a suitable candidate is found.お知らせ • Sep 06Albert Labs International Corp. Announces Resignation of Michael Raymont as Board of DirectorsAlbert Labs Management and Board of Director Announcement Effective immediately, Michael Raymont has resigned from his position of chief executive officer and director of Albert Labs International Corp., and Mike Thompson has resigned from the board of directors. The board of directors extends its sincerest gratitude to Mr. Raymont and Mr. Thompson for their contributions to the company. Chand Jagpal will be acting as the interim chief executive officer until a suitable candidate is found.Board Change • Jul 11No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Mar 21No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Feb 23No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 14Albert Labs International Corp. announced that it expects to receive CAD 0.3 million in fundingAlbert Labs International Corp. announced a non-brokered private placement of 6,250,000 units at an issue price d CAD 0.048 per unit for the gross proceeds of CAD 300,000 on February 13, 2023. Each Unit is comprised of one common share and one non-transferable Common Share purchase warrant and each full Warrant will be exercisable to acquire one common share of Albert Labs at an exercise price of CAD 0.07 for 24 months from the date of the closing of the transaction1825660439. The Company may decrease the size of the transaction. All securities issued in connection with the transaction will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation. The transaction is subject to regulatory approval in the United Kingdom and IND filing in the United States.Board Change • Feb 07No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jan 23No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 25Albert Labs International Corp. announced that it expects to receive CAD 3 million in fundingAlbert Labs International Corp. announced a non-brokered private placement of 37,500,000 units at a price of CAD 0.08 per unit for gross proceeds of up to CAD 3,000,000 on November 24, 2022. Each unit will consist of one common share and one common share purchase warrant. Each warrant will entitle the holder to purchase one common share at a price of CAD 0.12 for a period of twelve months. In the event that the company's common shares have a closing price on the Canadian Securities Exchange of greater than15 cents per common share for a period of 10 consecutive trading days, the company may accelerate the expiry date of the warrants by giving notice to the holders thereof and, in such case, the warrants will expire on the 30th day after the date on which such notice is given to the holder by the company. All securities issued in connection with the offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation. On the same date, the company received its first tranche. The tranche issued at a price of CAD 0.08.お知らせ • Nov 18Albert Labs Signs Letter of Intent (LOI) with Ingen CRO for First In-Human Clinical StudiesAlbert Labs International Corp. signs a Letter of Intent (LOI) with full-service Contract-Research Organisation (CRO), iNGEN, to carry out the Company's first in-human study of its primary drug target, KRN-101. This randomised, double-blind study will evaluate the safety and tolerability of KRN-101 in study participants and determine its full pharmacokinetic characterization. As a unique, natural medicine containing a range of bioactives, KRN-101 is required to have its own pharmacokinetic profile despite an extensive background of safety data to support psilocybin-based medicines. Profiling KRN-101 through this study will allow the Company to reap the long-term potential of having a differentiated product through extensive opportunities for intellectual property protection. This study will take place in Melbourne, Australia, and including the collection of all clinical outputs, will be carried out over 8 weeks with an expected completion in Third Quarter 2023. Upon completion, KRN-101 will be available for use in late-stage clinical trials, allowing the Company to proceed with its Real World Evidence trial in the United Kingdom, which will establish the efficacy of the treatment for cancer-related distress. This first in-human study also allows the Company to collect valuable data which will enable a future Investigational New Drug (IND) Application to be filed with the FDA, thus taking KRN-101 to the largest pharmaceutical market in the world.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 21Albert Labs Files New International PCT Patent Application for Scalable API ManufacturingAlbert Labs International Corp. has announced the filing of a New International PCT Patent Application (No. PCT/CA2022/051281) with the United States Patent and Trademark Office (USPTO) for its proprietary manufacturing process. This proprietary manufacturing methodology developed and validated in-house at Albert Labs' Vancouver facility facilitates the production and scaling of highly potent yields of its KRN-101 Active Pharmaceutical Ingredient. The bioreactor technology is efficient, economical, and sustainable, ensuring pharmaceutical quality and consistent production of its natural, tryptamine-based medicines The Company is utilising this proprietary manufacturing technology to produce its primary drug target, the psilocybin-based KRN-101, which will treat cancer patients suffering from mental distress. It will also support the company's growth plans as it pursues a clinical expansion strategy with various global regulatory authorities. Albert Labs is a pharmaceutical drug development company, focussed on gaining regulatory approval for active compounds in the treatment of mental health, and providing rapid access to effective prescription medicines for people suffering from mental health disorders. Its team of experts leverage advanced culture technology and natural extraction, coupled with a comprehensive regulatory approach, to accelerate the development of mental health drugs, for which the needs are both urgent and unmet. Albert Labs looks to develop solutions through an approved, fast track clinical pathway focusing on Real World Evidence (RWE). RWE studies are an increasingly recognised clinical route, heavily used in oncology and recently, in the successful development of COVID-19 vaccines. Through collaborations with research institutions, hospital centres and government agencies, Albert Labs uses existing clinical infrastructure to deliver and improve patient access to its treatment. Albert Labs' first drug target, KRN-101, is a potential solution for cancer-related anxiety, a market of over 15 million people with roughly 1 million new sufferers each year. From this initial focus, Albert Labs will address broader mental health concerns, reported to affect over a billion people worldwide. The company's goal is to deliver effective medicines to suffers with mental health concerns in the shortest possible time without compromising safety and/or quality, while also providing significant returns to shareholders.Board Change • Aug 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jul 12Albert Labs International Corp. Announces the Appointment of Mike Thompson MBE and Katie Shelton-Innes to Its BoardAlbert Labs International Corp. announced the appointment of Mike Thompson MBE and Katie Shelton-Innes to its Board. Mike Thompson, MBE joins Albert Labs as a prominent figure in Healthcare and Pharmaceuticals, bringing twenty-five years of experience in the Life Sciences sector. Between 2016 and 2019, Mike served as CEO at The Association of the British Pharmaceutical Industry (ABPI) and previously held senior positions at GSK in Global, European Regional and UK levels of the company. In 2021 Mike was awarded an MBE for services to medicines supply and resilience in the Queen's Birthday Honours List. During his time as CEO at the ABPI, Mike was at the forefront of UK drug approval and pricing policy, working hand-in-hand with Government bodies on behalf of the pharmaceutical industry. Amongst a number of considerable achievements in this role, Mike oversaw the agreement for £60bn of expenditure on branded pharmaceuticals, working closely with 10 Downing Street, HM Treasury and the Department of Health and Social Care. Katie Shelton-Innes is well-known in the United Kingdom for her work advising and raising funds for growth companies. She has a wealth of experience working for full-service investment banks, focussing on small to mid-cap companies, and was Head of Corporate Brokering at Arbuthnot Banking Group and Northland Capital Partners. Katie brings an astute knowledge of financial markets and a broad range of subsequent experiences and relationships. She joins the Albert Labs Board at a fitting time with the company exploring a listing in the United Kingdom while simultaneously scaling its operational functions across the UK, Canada and Portugal. Her appointment will consolidate the company's presence in the UK financial markets and support the company with its strategy for generating value for investors.お知らせ • May 13Albert Labs International Corp.' Pre-Clinical Analytical and Toxicological Research Supports Company's Forthcoming StudiesAlbert Labs International Corp. released further details of their ongoing preclinical studies. These are currently being conducted at the University of Health Sciences, CESPU, Portugal. The partnership established between Albert Labs and CESPU, provides Albert Labs with preclinical drug assessment capabilities, both in vivo and in vitro. The current work programme provides essential data on Albert Labs' mycelium-based pharmaceutical products in support of clinical trials due to start later this year. The clinical programme will investigate the potential to treat cancer-related distress, an indication thought to affect approximately 15 million patients worldwide. These pre-clinical studies, led by distinguished toxicologist, Dr. Ricardo Jorge Dinis-Oliveira, help to clarify the toxicological, pharmacokinetic and pharmacodynamic properties of Albert Labs' proprietary mycelium derived Active Pharmaceutical Ingredients (API). All preclinical work is conducted under Good Laboratory Practice ("GLP") guidelines and, through the OECD's Mutual Acceptance of Data scheme, will be accepted by leading health regulators such as the FDA and EMA. This data is needed prior to the commencement of Albert Labs' Real World Evidence (RWE) clinical trial with its first product candidate, KRN-101.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 27Albert Labs International Corp. Announces Board AppointmentsAlbert Labs International Corp. have strengthened their Scientific Advisory Board, with the addition of Professor Robert Britton, a Natural Product Chemist, and renowned toxicologist and pharmacologist, Dr. Dinis-Oliveira. Professor Robert Britton, BSc, PhD, of Simon Fraser University, is a well-published natural product chemist with globally recognized expertise in natural product drug discovery, medicinal chemistry, and cancer therapeutics. With a particular focus on oncology, Prof. Britton creates new tools for late-stage modification of drug leads, new processes for improving the manufacture of drugs, and new strategies for synthesizing structurally complex natural products. Prior to his academic career, Prof. Britton was a Senior Scientist in the Process Research Group at Merck. Dr. Ricardo Jorge Dinis-Oliveira, PhD, European PhD, DSc, is an expert Toxicologist and Pharmacologist. His scientific and academic focus is in the areas of toxicology and the pharmacology of psychoactive substances and medicines, focusing on their preclinical, and clinical development stages. He is a member of the editorial boards and ambassador to several international scientific journals.お知らせ • Mar 31Albert Labs International Corp. Files US Provisional Patent Application and Proves Out Consistent and Rapidly Scalable Production of Psilocybe and Other MyceliaAlbert Labs International Corp. filed provisional patent application with the United States Patent and Trademark Office for a proprietary process. Albert Labs' culturing process can significantly increase the production volumes of psilocybin medicine. The Company sees the demand for naturally produced psilocybin continuing to increase as the unmet needs for mental health treatment hit crisis levels worldwide. The improved quality and consistency enabled by this patent-pending process are paramount to scaling the Eu-GMP production of psilocybin Active Pharmaceutical Ingredient. The new process and methodology optimized key parameters necessary for the efficient cultivation that results in an increased high-quality yield of Psilocybe mycelia. The same patent-pending process and methodology can also be applied to the optimized cultivation of other fungi species, opening up the untapped potential market of bio-active fungal compounds. This is not a synthetic or biosynthetic process and does not use or introduce harmful synthetic chemicals or genetically modified bacteria in the production of psilocybin. Batch to batch, Albert Labs' bioreactor design allows them to produce strong yields of consistent psilocybin API, which will continue to be assessed for clinical efficacy and safety through Albert Labs' upcoming real-world evidence trials.株主還元ABRTCA BiotechsCA 市場7D0%3.9%2.8%1Y-50.0%-1.4%32.0%株主還元を見る業界別リターン: ABRT過去 1 年間で-1.4 % の収益を上げたCanadian Biotechs業界を下回りました。リターン対市場: ABRTは、過去 1 年間で32 % のリターンを上げたCanadian市場を下回りました。価格変動Is ABRT's price volatile compared to industry and market?ABRT volatilityABRT Average Weekly Movementn/aBiotechs Industry Average Movement11.1%Market Average Movement10.1%10% most volatile stocks in CA Market17.6%10% least volatile stocks in CA Market3.8%安定した株価: ABRTの株価は、 Canadian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のABRTのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aChand Jagpalalbertlabs.comアルバート・ラボ・インターナショナル社は、バイオ医薬品の創薬企業であり、カナダと英国において、緊急かつアンメットニーズのある患者のためのサイケデリック補助療法のための薬剤を研究開発している。同社が開発したKRN-101は、がんに関連した不安の解決薬である。本社はカナダのバーナビー。もっと見るAlbert Labs International Corp. 基礎のまとめAlbert Labs International の収益と売上を時価総額と比較するとどうか。ABRT 基礎統計学時価総額CA$372.07k収益（TTM）-CA$2.31m売上高(TTM)n/a0.0xP/Sレシオ-0.2xPER（株価収益率ABRT は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ABRT 損益計算書（TTM）収益CA$0売上原価CA$0売上総利益CA$0その他の費用CA$2.31m収益-CA$2.31m直近の収益報告Sep 30, 2023次回決算日該当なし一株当たり利益（EPS）-0.031グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-2.3%ABRT の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/10/13 19:32終値2024/07/16 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Albert Labs International Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jun 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$492k free cash flow). Shares are highly illiquid. Negative equity (-CA$443k). Revenue is less than US$1m. Market cap is less than US$10m (CA$744.1k market cap, or US$541.9k). Minor Risk Latest financial reports are more than 6 months old (reported September 2023 fiscal period end).
Board Change • Mar 13No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jan 11No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Dec 08No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 19Albert Labs International Corp. Appoints Shabir Hasham to Its Board of DirectorsAlbert Labs International Corp. announced the appointment of Dr. Shabir Hasham to its Board of Directors. With an impressive 20 years of distinguished industry experience, Dr. Hasham brings a wealth of expertise to guide Albert Labs in its mission to revolutionize mental health solutions. Dr. Hasham's exceptional career is marked by his proficiency in navigating regulatory bodies, including the FDA and MHRA, ensuring successful product launches and compliance. His regulatory acumen aligns seamlessly with Albert Labs' commitment to delivering innovative mental health solutions. As the former EU Medical Director for the Neuroscience Franchise at Novartis, Dr. Hasham played a pivotal role in advancing pharmaceutical solutions. His leadership is a testament to his deep understanding of the complexities involved in bringing transformative medicines to market. Dr. Shabir Hasham's arrival marks a reunion with former team members, including Chief Medical Officer Dr. Malcolm Barrett Johnson and Chief Operations Officer Santoke Naal. His past collaborations with these key individuals, particularly during their tenure at Novartis, underscore Dr. Hasham's exceptional ability to drive successful outcomes in a collaborative environment. In addition to his 20 years of experience, Dr. Shabir Hasham will be progressively taking on an increased leadership role within Albert Labs. His informal leadership style, combined with strategic planning and operational excellence, aligns seamlessly with the company's vision for transformative solutions in mental health pharmaceuticals. Dr. Hasham possesses a unique proficiency in dealing with biotechnology and healthcare investment funds. His strategic insights have effectively guided investments, contributing to the success of various projects. Dr. Hasham's ability to communicate complex ideas in the right manner has been instrumental in securing support from investment entities, and ensuring alignment with organizational goals. Albert Labs looks forward to leveraging Dr. Shabir Hasham's multifaceted expertise as the company continues its pursuit of excellence in mental health pharmaceuticals.
お知らせ • Sep 07Albert Labs International Corp. Announces CEO ChangesAlbert Labs Management and Board of Director Announcement Effective immediately, Michael Raymont has resigned from his position of chief executive officer and director of Albert Labs International Corp., and Mike Thompson has resigned from the board of directors. The board of directors extends its sincerest gratitude to Mr. Raymont and Mr. Thompson for their contributions to the company. Chand Jagpal will be acting as the interim chief executive officer until a suitable candidate is found.
New Risk • Jun 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$492k free cash flow). Shares are highly illiquid. Negative equity (-CA$443k). Revenue is less than US$1m. Market cap is less than US$10m (CA$744.1k market cap, or US$541.9k). Minor Risk Latest financial reports are more than 6 months old (reported September 2023 fiscal period end).
Board Change • Mar 13No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jan 11No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Dec 08No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 19Albert Labs International Corp. Appoints Shabir Hasham to Its Board of DirectorsAlbert Labs International Corp. announced the appointment of Dr. Shabir Hasham to its Board of Directors. With an impressive 20 years of distinguished industry experience, Dr. Hasham brings a wealth of expertise to guide Albert Labs in its mission to revolutionize mental health solutions. Dr. Hasham's exceptional career is marked by his proficiency in navigating regulatory bodies, including the FDA and MHRA, ensuring successful product launches and compliance. His regulatory acumen aligns seamlessly with Albert Labs' commitment to delivering innovative mental health solutions. As the former EU Medical Director for the Neuroscience Franchise at Novartis, Dr. Hasham played a pivotal role in advancing pharmaceutical solutions. His leadership is a testament to his deep understanding of the complexities involved in bringing transformative medicines to market. Dr. Shabir Hasham's arrival marks a reunion with former team members, including Chief Medical Officer Dr. Malcolm Barrett Johnson and Chief Operations Officer Santoke Naal. His past collaborations with these key individuals, particularly during their tenure at Novartis, underscore Dr. Hasham's exceptional ability to drive successful outcomes in a collaborative environment. In addition to his 20 years of experience, Dr. Shabir Hasham will be progressively taking on an increased leadership role within Albert Labs. His informal leadership style, combined with strategic planning and operational excellence, aligns seamlessly with the company's vision for transformative solutions in mental health pharmaceuticals. Dr. Hasham possesses a unique proficiency in dealing with biotechnology and healthcare investment funds. His strategic insights have effectively guided investments, contributing to the success of various projects. Dr. Hasham's ability to communicate complex ideas in the right manner has been instrumental in securing support from investment entities, and ensuring alignment with organizational goals. Albert Labs looks forward to leveraging Dr. Shabir Hasham's multifaceted expertise as the company continues its pursuit of excellence in mental health pharmaceuticals.
お知らせ • Sep 07Albert Labs International Corp. Announces CEO ChangesAlbert Labs Management and Board of Director Announcement Effective immediately, Michael Raymont has resigned from his position of chief executive officer and director of Albert Labs International Corp., and Mike Thompson has resigned from the board of directors. The board of directors extends its sincerest gratitude to Mr. Raymont and Mr. Thompson for their contributions to the company. Chand Jagpal will be acting as the interim chief executive officer until a suitable candidate is found.
お知らせ • Sep 06Albert Labs International Corp. Announces Resignation of Michael Raymont as Board of DirectorsAlbert Labs Management and Board of Director Announcement Effective immediately, Michael Raymont has resigned from his position of chief executive officer and director of Albert Labs International Corp., and Mike Thompson has resigned from the board of directors. The board of directors extends its sincerest gratitude to Mr. Raymont and Mr. Thompson for their contributions to the company. Chand Jagpal will be acting as the interim chief executive officer until a suitable candidate is found.
Board Change • Jul 11No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Mar 21No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Feb 23No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 14Albert Labs International Corp. announced that it expects to receive CAD 0.3 million in fundingAlbert Labs International Corp. announced a non-brokered private placement of 6,250,000 units at an issue price d CAD 0.048 per unit for the gross proceeds of CAD 300,000 on February 13, 2023. Each Unit is comprised of one common share and one non-transferable Common Share purchase warrant and each full Warrant will be exercisable to acquire one common share of Albert Labs at an exercise price of CAD 0.07 for 24 months from the date of the closing of the transaction1825660439. The Company may decrease the size of the transaction. All securities issued in connection with the transaction will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation. The transaction is subject to regulatory approval in the United Kingdom and IND filing in the United States.
Board Change • Feb 07No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jan 23No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 25Albert Labs International Corp. announced that it expects to receive CAD 3 million in fundingAlbert Labs International Corp. announced a non-brokered private placement of 37,500,000 units at a price of CAD 0.08 per unit for gross proceeds of up to CAD 3,000,000 on November 24, 2022. Each unit will consist of one common share and one common share purchase warrant. Each warrant will entitle the holder to purchase one common share at a price of CAD 0.12 for a period of twelve months. In the event that the company's common shares have a closing price on the Canadian Securities Exchange of greater than15 cents per common share for a period of 10 consecutive trading days, the company may accelerate the expiry date of the warrants by giving notice to the holders thereof and, in such case, the warrants will expire on the 30th day after the date on which such notice is given to the holder by the company. All securities issued in connection with the offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation. On the same date, the company received its first tranche. The tranche issued at a price of CAD 0.08.
お知らせ • Nov 18Albert Labs Signs Letter of Intent (LOI) with Ingen CRO for First In-Human Clinical StudiesAlbert Labs International Corp. signs a Letter of Intent (LOI) with full-service Contract-Research Organisation (CRO), iNGEN, to carry out the Company's first in-human study of its primary drug target, KRN-101. This randomised, double-blind study will evaluate the safety and tolerability of KRN-101 in study participants and determine its full pharmacokinetic characterization. As a unique, natural medicine containing a range of bioactives, KRN-101 is required to have its own pharmacokinetic profile despite an extensive background of safety data to support psilocybin-based medicines. Profiling KRN-101 through this study will allow the Company to reap the long-term potential of having a differentiated product through extensive opportunities for intellectual property protection. This study will take place in Melbourne, Australia, and including the collection of all clinical outputs, will be carried out over 8 weeks with an expected completion in Third Quarter 2023. Upon completion, KRN-101 will be available for use in late-stage clinical trials, allowing the Company to proceed with its Real World Evidence trial in the United Kingdom, which will establish the efficacy of the treatment for cancer-related distress. This first in-human study also allows the Company to collect valuable data which will enable a future Investigational New Drug (IND) Application to be filed with the FDA, thus taking KRN-101 to the largest pharmaceutical market in the world.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 21Albert Labs Files New International PCT Patent Application for Scalable API ManufacturingAlbert Labs International Corp. has announced the filing of a New International PCT Patent Application (No. PCT/CA2022/051281) with the United States Patent and Trademark Office (USPTO) for its proprietary manufacturing process. This proprietary manufacturing methodology developed and validated in-house at Albert Labs' Vancouver facility facilitates the production and scaling of highly potent yields of its KRN-101 Active Pharmaceutical Ingredient. The bioreactor technology is efficient, economical, and sustainable, ensuring pharmaceutical quality and consistent production of its natural, tryptamine-based medicines The Company is utilising this proprietary manufacturing technology to produce its primary drug target, the psilocybin-based KRN-101, which will treat cancer patients suffering from mental distress. It will also support the company's growth plans as it pursues a clinical expansion strategy with various global regulatory authorities. Albert Labs is a pharmaceutical drug development company, focussed on gaining regulatory approval for active compounds in the treatment of mental health, and providing rapid access to effective prescription medicines for people suffering from mental health disorders. Its team of experts leverage advanced culture technology and natural extraction, coupled with a comprehensive regulatory approach, to accelerate the development of mental health drugs, for which the needs are both urgent and unmet. Albert Labs looks to develop solutions through an approved, fast track clinical pathway focusing on Real World Evidence (RWE). RWE studies are an increasingly recognised clinical route, heavily used in oncology and recently, in the successful development of COVID-19 vaccines. Through collaborations with research institutions, hospital centres and government agencies, Albert Labs uses existing clinical infrastructure to deliver and improve patient access to its treatment. Albert Labs' first drug target, KRN-101, is a potential solution for cancer-related anxiety, a market of over 15 million people with roughly 1 million new sufferers each year. From this initial focus, Albert Labs will address broader mental health concerns, reported to affect over a billion people worldwide. The company's goal is to deliver effective medicines to suffers with mental health concerns in the shortest possible time without compromising safety and/or quality, while also providing significant returns to shareholders.
Board Change • Aug 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Katie Shelton-Innes was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 12Albert Labs International Corp. Announces the Appointment of Mike Thompson MBE and Katie Shelton-Innes to Its BoardAlbert Labs International Corp. announced the appointment of Mike Thompson MBE and Katie Shelton-Innes to its Board. Mike Thompson, MBE joins Albert Labs as a prominent figure in Healthcare and Pharmaceuticals, bringing twenty-five years of experience in the Life Sciences sector. Between 2016 and 2019, Mike served as CEO at The Association of the British Pharmaceutical Industry (ABPI) and previously held senior positions at GSK in Global, European Regional and UK levels of the company. In 2021 Mike was awarded an MBE for services to medicines supply and resilience in the Queen's Birthday Honours List. During his time as CEO at the ABPI, Mike was at the forefront of UK drug approval and pricing policy, working hand-in-hand with Government bodies on behalf of the pharmaceutical industry. Amongst a number of considerable achievements in this role, Mike oversaw the agreement for £60bn of expenditure on branded pharmaceuticals, working closely with 10 Downing Street, HM Treasury and the Department of Health and Social Care. Katie Shelton-Innes is well-known in the United Kingdom for her work advising and raising funds for growth companies. She has a wealth of experience working for full-service investment banks, focussing on small to mid-cap companies, and was Head of Corporate Brokering at Arbuthnot Banking Group and Northland Capital Partners. Katie brings an astute knowledge of financial markets and a broad range of subsequent experiences and relationships. She joins the Albert Labs Board at a fitting time with the company exploring a listing in the United Kingdom while simultaneously scaling its operational functions across the UK, Canada and Portugal. Her appointment will consolidate the company's presence in the UK financial markets and support the company with its strategy for generating value for investors.
お知らせ • May 13Albert Labs International Corp.' Pre-Clinical Analytical and Toxicological Research Supports Company's Forthcoming StudiesAlbert Labs International Corp. released further details of their ongoing preclinical studies. These are currently being conducted at the University of Health Sciences, CESPU, Portugal. The partnership established between Albert Labs and CESPU, provides Albert Labs with preclinical drug assessment capabilities, both in vivo and in vitro. The current work programme provides essential data on Albert Labs' mycelium-based pharmaceutical products in support of clinical trials due to start later this year. The clinical programme will investigate the potential to treat cancer-related distress, an indication thought to affect approximately 15 million patients worldwide. These pre-clinical studies, led by distinguished toxicologist, Dr. Ricardo Jorge Dinis-Oliveira, help to clarify the toxicological, pharmacokinetic and pharmacodynamic properties of Albert Labs' proprietary mycelium derived Active Pharmaceutical Ingredients (API). All preclinical work is conducted under Good Laboratory Practice ("GLP") guidelines and, through the OECD's Mutual Acceptance of Data scheme, will be accepted by leading health regulators such as the FDA and EMA. This data is needed prior to the commencement of Albert Labs' Real World Evidence (RWE) clinical trial with its first product candidate, KRN-101.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 27Albert Labs International Corp. Announces Board AppointmentsAlbert Labs International Corp. have strengthened their Scientific Advisory Board, with the addition of Professor Robert Britton, a Natural Product Chemist, and renowned toxicologist and pharmacologist, Dr. Dinis-Oliveira. Professor Robert Britton, BSc, PhD, of Simon Fraser University, is a well-published natural product chemist with globally recognized expertise in natural product drug discovery, medicinal chemistry, and cancer therapeutics. With a particular focus on oncology, Prof. Britton creates new tools for late-stage modification of drug leads, new processes for improving the manufacture of drugs, and new strategies for synthesizing structurally complex natural products. Prior to his academic career, Prof. Britton was a Senior Scientist in the Process Research Group at Merck. Dr. Ricardo Jorge Dinis-Oliveira, PhD, European PhD, DSc, is an expert Toxicologist and Pharmacologist. His scientific and academic focus is in the areas of toxicology and the pharmacology of psychoactive substances and medicines, focusing on their preclinical, and clinical development stages. He is a member of the editorial boards and ambassador to several international scientific journals.
お知らせ • Mar 31Albert Labs International Corp. Files US Provisional Patent Application and Proves Out Consistent and Rapidly Scalable Production of Psilocybe and Other MyceliaAlbert Labs International Corp. filed provisional patent application with the United States Patent and Trademark Office for a proprietary process. Albert Labs' culturing process can significantly increase the production volumes of psilocybin medicine. The Company sees the demand for naturally produced psilocybin continuing to increase as the unmet needs for mental health treatment hit crisis levels worldwide. The improved quality and consistency enabled by this patent-pending process are paramount to scaling the Eu-GMP production of psilocybin Active Pharmaceutical Ingredient. The new process and methodology optimized key parameters necessary for the efficient cultivation that results in an increased high-quality yield of Psilocybe mycelia. The same patent-pending process and methodology can also be applied to the optimized cultivation of other fungi species, opening up the untapped potential market of bio-active fungal compounds. This is not a synthetic or biosynthetic process and does not use or introduce harmful synthetic chemicals or genetically modified bacteria in the production of psilocybin. Batch to batch, Albert Labs' bioreactor design allows them to produce strong yields of consistent psilocybin API, which will continue to be assessed for clinical efficacy and safety through Albert Labs' upcoming real-world evidence trials.
